Taken together, newly developed GSK-3β inhibitors for the treatment of ALS should have an optimal and balanced inhibitory effect on GSK-3β, and the appropriate dose needs to be carefully examined. The gene discussed is GSK3B; the disease is amyotrophic lateral sclerosis.